Literature DB >> 25999247

Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori.

Priscila Baptistella Yazbek1, Ariane Biolcati Trindade1, Chung Man Chin1, Jean Leandro Dos Santos2.   

Abstract

Helicobacter pylori (H. pylori) is one of the leading causes of gastric diseases such as chronic gastritis, peptic ulcer, and gastric adenocarcinoma. The current treatment of H. pylori infection with antibiotics and proton pump inhibitors has several limitations, including poor adherence and intrinsic patient-related factors, drug resistance, and the absence of adequate treatments. This review summarizes the current therapeutic approaches to eradicating H. pylori, the difficulties associated with its treatment, and several new perspectives aimed at improving existing treatment strategies.

Entities:  

Keywords:  Gastric diseases; H. pylori eradication; H. pylori resistance; Helicobacter pylori; Treatment

Mesh:

Substances:

Year:  2015        PMID: 25999247     DOI: 10.1007/s10620-015-3712-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  6 in total

Review 1.  Helicobacter pylori infection.

Authors:  Sebastian Suerbaum; Pierre Michetti
Journal:  N Engl J Med       Date:  2002-10-10       Impact factor: 91.245

2.  Effects of alpha tocopherol and ascorbic acid on Helicobacter pylori colonization and the severity of gastric inflammation.

Authors:  Mesut Sezikli; Züleyha Akkan Çetinkaya; Fatih Güzelbulut; Burak Çimen; Ömer Özcan; Selvinaz Özkara; Atakan Yeşil; Gülistan Gümrükçü; Osman Metin Ipçioğlu; Hayrünnisa Sezikli; Ayşe Oya Kurdaş Ovünç
Journal:  Helicobacter       Date:  2012-04       Impact factor: 5.753

Review 3.  Epidemiology of Helicobacter pylori infection.

Authors:  Philippe Lehours; Ozlem Yilmaz
Journal:  Helicobacter       Date:  2007-10       Impact factor: 5.753

4.  Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis.

Authors:  Guogang Li; Lan Li; Chaohui Yu; Li Chen
Journal:  Br J Nutr       Date:  2011-08-03       Impact factor: 3.718

5.  CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina: fermentation, isolation, structural elucidation and biological activities.

Authors:  K A Dekker; T Inagaki; T D Gootz; K Kaneda; E Nomura; T Sakakibara; S Sakemi; Y Sugie; Y Yamauchi; N Yoshikawa; N Kojima
Journal:  J Antibiot (Tokyo)       Date:  1997-10       Impact factor: 2.649

6.  In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection.

Authors:  T Kanamaru; Y Nakano; Y Toyoda; K I Miyagawa; M Tada; T Kaisho; M Nakao
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

  6 in total
  4 in total

Review 1.  Hybrid, sequential and concomitant therapies for Helicobacter pylori eradication: A systematic review and meta-analysis.

Authors:  Zhi-Qiang Song; Li-Ya Zhou
Journal:  World J Gastroenterol       Date:  2016-05-21       Impact factor: 5.742

2.  Early Attempts to Eradicate Helicobacter pylori after Endoscopic Resection of Gastric Neoplasm Significantly Improve Eradication Success Rates.

Authors:  Cheal Wung Huh; Young Hoon Youn; Da Hyun Jung; Jae Jun Park; Jie-Hyun Kim; Hyojin Park
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

3.  Gastroprotective Value of Berries: Evidences from Methanolic Extracts of Morus nigra and Rubus niveus Fruits.

Authors:  Luciane Angela Nottar Nesello; Maria Luisa Maes Lima Beleza; Marihá Mariot; Luísa Nathália Bolda Mariano; Priscila de Souza; Adriana Campos; Valdir Cechinel-Filho; Sérgio Faloni Andrade; Luísa Mota da Silva
Journal:  Gastroenterol Res Pract       Date:  2017-09-20       Impact factor: 2.260

4.  ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Authors:  Stanley L Marks; Peter H Kook; Mark G Papich; M K Tolbert; Michael D Willard
Journal:  J Vet Intern Med       Date:  2018-10-31       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.